K145 significantly reduced tumor growth (Fig. 7d) and, consistent with the effects of IC1 re-expression (Fig. 5e), targeting SK2 with K145 also reduced tumor vasculature as signified by a reduction in CD31-positive blood vessels (Fig. 7e). Here, PECAM1 is linked to neoplasm.